

SuperScript[™] III Platinum[®] SYBR[®] Green One-Step qRT-PCR SuperMix with BSA

Cat. no. 11750-100 Cat. no. 11750-500

Size: 96 reactions Size: 480 reactions Store at -20°C

Description

SuperScript[™] III Platinum[®] SYBR[®] Green One-Step qRT-PCR SuperMix with BSA is a ready-to-use reaction mix for one-step, real-time quantitative RT-PCR (qRT-PCR) that has been specifically formulated for use with the Roche LightCycler[®]. The SuperMix combines the high-temperature reverse transcription capability of SuperScript[™] III Reverse Transcriptase (RT), the automatic hot-start PCR provided by Platinum[®] *Taq* DNA Polymerase, and the fluorescent binding dye SYBR[®] Green I for optimal specificity, consistency, and efficiency. Both cDNA synthesis and PCR are performed in the same tube using gene-specific primers and RNA target(s) from either total RNA or mRNA. All components necessary for qRT-PCR are combined in the tube, and reverse transcription is directly followed by PCR cycling without additional handling.

The SuperMix formulation enables highly sensitive detection down to 0.1 pg of total RNA, and has a broad quantification range from 1 pg to 1 μ g of total RNA. It is provided at 2.5X concentration, and includes SuperScript[™] III RT; Platinum[®] *Taq* DNA Polymerase; SYBR[®] Green I dye; 7.5 mM MgCl₂; dNTPs; ultrapure, nonacetylated bovine serum albumin (BSA); a proprietary buffer system; and stabilizers.

SuperScript[™] III Reverse Transcriptase is a version of M-MLV RT that has been engineered to reduce RNase H activity and provide increased thermal stability (1, 2). The enzyme can be used to synthesize cDNA at a temperature range of 42–60°C, providing increased specificity, higher yields of cDNA, and more full-length product than other reverse transcriptases. Because SuperScript[™] III RT is not significantly inhibited by ribosomal and transfer RNA, it can be used to synthesize cDNA from total RNA.

Platinum[®] *Taq* DNA polymerase is recombinant *Taq* DNA polymerase complexed with a proprietary antibody that blocks polymerase activity at ambient temperatures (3, 4, 5). Activity is restored after the denaturation step in PCR cycling, providing an automatic "hot start" in PCR for increased sensitivity, specificity, and yield.

SYBR[®] Green I is a fluorescent dye that binds directly to double-stranded DNA (dsDNA). In qPCR, as dsDNA accumulates, the dye generates a signal that is proportional to the DNA concentration and that can be detected using real-time qPCR instruments (2, 3). SYBR[®] Green I in this formulation can detect as few as 10 copies of a target gene in as little as 0.1 pg of total RNA, has a wide dynamic range, and is compatible with melting curve analysis.

Special stabilizers are included in the SuperMix to reduce nonspecific amplification products. Ultrapure, nonacetylated BSA is included because the glass capillaries in the LightCycler[®] have a high surface-to-volume ratio and the glass surface binds molecules such as *Taq* DNA polymerase. The addition of BSA blocks this surface binding.

A tube of 50-mM MgCl₂ is included in the SuperMix for further optimization of the Mg^{2+} concentration. Reagents are provided for 96 or 480 amplification reactions of 20 μ l each.

<u>Component</u>	<u>96-Rxn Kit</u>	<u>480-Rxn Kit</u>
2.5X SYBR® Green One-Step SuperMix with BSA	770 µl	3×1.3 ml
50-mM Magnesium Chloride (MgCl ₂)	1 ml	$2 \times 1 \text{ ml}$

Storage

Store components in the dark at -20°C.

Additional Products

<u>Product</u> SuperScript [™] III Platinum [®] SYBR [®] Green One-Step qRT-PCR Kit with ROX	<u>Amount</u> 100 rxns 500 rxns	<u>Catalog no.</u> 11746-100 11746-500
PureLink [™] Micro-to-Midi [™] Total RNA Purification System	50 rxns	12183-018
TRIzol [®] Reagent	100 ml 200 ml	15596-026 15596-018
PureLink [™] 96 Total RNA Purification Kit	384 rxns	12173-011
RNaseOUT [™] Recombinant Ribonuclease Inhibitor	5000 units	10777-019
DNase I, Amplification Grade	100 units	18068-015
Custom Primers	to order, visit <u>ww</u>	w.invitrogen.com

Part no. 11750.pps

Rev. date: 18 October 2010

For research use only. Not intended for any animal or human therapeutic or diagnostic use.

For technical support, contact tech_service@invitrogen.com.

Recommendations and Guidelines for Quantitative RT-PCR

RNA

- Starting material can range from 0.1 pg to 1 µg of purified total RNA. High-quality, intact RNA is essential for full-length, high-quality cDNA synthesis and accurate mRNA quantification.
- RNA should be devoid of any RNase contamination and aseptic conditions should be maintained. **Optional:** An RNase inhibitor protein, such as RNaseOUT[™] Recombinant Ribonuclease Inhibitor (Cat. no. 10777-019), may be added to the reaction after the SuperMix to safeguard against degradation of target RNA due to ribonuclease contamination of the RNA preparation.
- To isolate total RNA, we recommend the PureLink[™] Micro-to-Midi[™] Total RNA Purification System (Cat. no. 12183-018), TRIzol[®] Reagent (Cat. nos. 15596-026 and 15596-018), or the PureLink[™] 96 Total RNA Purification Kit for high-throughput applications (Cat. no. 12173-011). Isolation of mRNA from total RNA is typically not necessary, although incorporating this step may improve the yield of specific cDNAs.
- RNA may be treated with DNase I (Catalog no. 18068-015) to remove any contaminating genomic DNA.

Instrument Settings

This SuperMix is specifically formulated for use with the Roche LightCycler[®]. General instrument settings are provided in the protocol on page 3. Refer to your instrument manual for detailed operating instructions.

Melting Curve Analysis

Melting curve analysis should always be performed during real-time qPCR to identify the presence of primer dimers and analyze the specificity of the reaction.

Melting curve analysis can identify primer dimers by their lower melting temperature compared to that of the amplicon. The presence of primer dimers in samples containing template decreases PCR efficiency and obscures analysis and determination of cycle thresholds. The formation of primer dimers most often occurs in notemplate controls, where the polymerase enzyme is essentially idle, and in this case the quantitative analysis of the template samples is not affected. Melting curve analysis of no-template controls can discriminate between primer dimers and spurious amplification due to contaminating nucleic acids in reagent components.

Reaction Setup and Conditions

- Keep all components and samples on ice.
- Efficient cDNA synthesis can be accomplished in a 2–10-minute incubation at 42–55°C. Optimal temperature varies for different primers and templates. A good general starting point is 50°C for 2 minutes. For problematic templates, or to increase the specificity of cDNA priming, increase the cDNA synthesis temperature to 55°C.
- During the 2-minute incubation at 95°C, SuperScript[™] III RT is inactivated, the RNA/cDNA hybrid is denatured, and Platinum[®] *Taq* DNA polymerase is activated.
- The annealing temperature should be 0–10°C below the melting temperature of the primers used.
- The extension time of 10 seconds is appropriate for the short amplicons that are typically used in qPCR.

TRIzol[®] is a registered trademark of Molecular Research Center, Inc. LightCycler[®] is a registered trademark of Idaho Technologies, Inc.

Primers

- Gene-specific primers are required. We do not recommend using oligo(dT) or random primers, which may generate nonspecific products in the one-step procedure and reduce the amount of product.
- Primer selection is one of the most important parameters when using a SYBR[®] Green detection system. To design primers, we strongly recommend using a primer design software program such as OligoPerfect[™] Designer (on the Web at <u>www.invitrogen.com/oligoperfect</u>). In OligoPerfect[™], you enter your target sequence and select *PCR: Detection* from the Application pulldown menu to access the appropriate design parameters for qPCR applications. Invitrogen's Vector NTI[™] software can also be used to design primers. Primer design software will ensure that primers are specific for the target sequence and free of internal secondary structure, and avoid complementation at 3'-ends within each primer and with each other.
- Design primers that anneal to exons on both sides of an intron or within the exon/exon boundary of the mRNA to allow differentiation between amplification of cDNA and potential contaminating genomic DNA.
- For best results, the amplicon size should be limited to 80–200 bp.
- A final concentration of 500 nM per primer is effective for most reactions. Optimal results may require a primer titration.

Magnesium Concentration

The 2.5X SuperMix supplies a final magnesium concentration of 3 mM. This works well for most targets; however, the optimal magnesium concentration in qRT-PCR may vary between 3 and 6 mM.

If necessary, use the 50-mM magnesium chloride solution included in the SuperMix to increase the magnesium concentration. Use the following table to determine the amount of additional $MgCl_2$ necessary to achieve the specified concentration (in a 20-µl reaction with 8 µl of SuperMix):

<u>For a final MgCl₂ conc. of</u>	<u>Add 50-mM MgCl2 (per 20-µl Rxn)</u>
4.0 mM	0.4 µl
5.0 mM	0.8 µl
6.0 mM	1.2 µl

Decrease the amount of water in the reaction accordingly.

Note: Increasing the magnesium concentration may also increase the level of nonspecific amplification products, such as primer dimers. To reduce the level of nonspecific products, you may need to reduce the concentration of primers in the reaction.

Roche LightCycler[®] Protocol

The protocol below summarizes the cycling conditions and reaction components for one-step qRT-PCR on the Roche LightCycler[®]. The SuperMix is provided at a 2.5X concentration to allow for 8 μ l of SuperMix, 1 μ l of each primer, and up to 10 μ l of template in a 20- μ l reaction volume.

1. Program the LightCycler[®] to perform cDNA synthesis immediately followed by PCR amplification, as specified below. Optimal temperatures and incubation times may vary for different target sequences (see **Reaction Setup and Conditions**, previous page).

PCR Cycling	Melting Curve Analysis
Program choice: Amplification	Program choice: Melting curve
Analysis mode: Quantification	Analysis mode: Melting curves
50°C for 2 minutes hold	95℃, 0 seconds
95°C for 2 minutes hold	55°C, 10 seconds
45 cycles of:	95°C, 10 seconds (slope set at 0.1°C/second, continuous acquisition)
95°C, 5 seconds	40°C, 0 seconds
55°C, 10 seconds (single acquire)	
72°C, 10 seconds	

2. Prepare a master mix on ice of all components except template. **Note**: Preparation of a master mix is **crucial** in quantitative applications to reduce pipetting errors.

Component	1 reaction	34 reactions
2.5X SYBR® Green One-Step SuperMix with BSA	8 µl	272 µl
Forward primer, 10 µM	1 µl	34 µl
Reverse primer, 10 µM	1 µl	34 µl
DEPC-treated water	x μl *	x μl *

* The amount of water depends on the amount of template you will add for a final reaction volume of 20 µl.

- 3. Add a single reaction volume of the master mix to each LightCycler[®] glass capillary tube.
- 4. Add 2–10 μl of sample RNA (0.1 pg to 1 μg total RNA) to each capillary tube, for a final reaction volume of 20 μl.
- 5. Gently mix and make sure that all components are at the bottom of the tube. Centrifuge briefly if needed.
- 6. Place reactions in the LightCycler® programmed as described above. Collect and analyze the results.

Quality Control

The product is tested functionally by quantitative real-time analysis using total HeLa RNA as template. Kinetic analysis must demonstrate a linear dose response with decreasing target concentration and detection of β -actin mRNA in 1 pg of total HeLa RNA.

References

- 1. Kotewicz, M.L., D'Alessio, J.M., Driftmier, K.M., Blodgett, K.P., and Gerard, G.F. (1985) Gene 35, 249.
- 2. Gerard, G.F., D'Alessio, J.M., Kotewicz, M.L., and Noon, M.C. (1986) DNA 5, 271.
- 3. Chou, Q., Russel, M., Birch, D., Raymond, J., and Bloch, W. (1992) Nucl. Acids Res. 20, 1717.
- 4. Sharkey, D.J., Scalice, E.R., Christy, K.G., Atwood, S.M., and Daiss, J.L. (1994) BioTechnology 12, 506.
- 5. Westfall, B., Sitaraman, K., Hughes, J., and Rashtchian, A. (1997) Focus® 19, 46.
- 6. Lowe, B., Avila, H. A., Bloom, F., Gleeson, M., and Kusser, W. (2003) Anal. Biochem. 315, 95.
- 7. Nazarenko I., Lowe, B., Darfler, M., Ikonomi, P., Schuster, D., and Rashtchian, A. (2002) Nucleic Acids Res. 30, e37.
- 8. Tyagi, S. and Kramer, F.R. (1996) Nature Biotechnology 14, 303.
- 9. Tyagi, S., Bratu, D.P., and Kramer, F.R. (1998) Nature Biotechnology 16, 49.
- 10. Kostrikis, L.G., Tyagi, S., Mhlanga, M.M., Ho, D.D., and Kramer, F.R. (1998) Science 279, 1228.
- 11 Holland, P.M., Abramson, R.D., Watson, R., and Gelfand, D. H. (1991) Proc. Natl. Acad. Sci. USA 88, 7276.
- 12. Gibson, U. E. M., Heid, C. A., and Williams, P.M. (1996) Genome Res. 6, 995.
- 13. Heid, C. A., Stevens, J., Livak, K. J., and Williams, P. M. (1996) Genome Res. 6, 986.
- 14. Nazarenko, I.A., Bhatnagar, S.K., and Hohman, R.J. (1997) Nucl. Acids Res. 25, 2516.
- 15. Wittwer, C.T., Herrmann, M.G., Moss, A.A., and Rasmussen, R.P. (1997) Biotechniques 22,130.
- 16. Ishiguro, T., Saitoh, J., Yawata, H., Yamagishi, H., Iwasaki, S., and Mitoma, Y. (1995) Anal. Biochem. 229, 207.
- 17. Berger, S.L. and Kimmel, A.R. (1987) Methods in Enzymol. 152, 316.
- 18. Gerard, G. F. (1994) Focus[®] 16, 102.

Troubleshooting Guide

Problem	Possible Cause	Probable Solution
No amplification product	Problem with instrument settings	Run the sample on a gel to determine if PCR product was generated. If the appropriate bands are seen, check the instrument settings
Relative fluorescent signal ≤ background or no template control	cDNA synthesis temperature too high, low priming efficiency	Lower incubation temperature.
	RT or cDNA primer blocked by secondary structure	Raise incubation temperature. Redesign primer(s).
	RNA has been damaged or degraded RNase contamination	Replace RNA if necessary.
		Maintain aseptic conditions.
Poor sensitivity, or	Not enough starting template RNA	Increase the concentration of template RNA; use 10 ng to $1 \mu g$ of total RNA.
product detected at higher than expected cycle number	RNA has been damaged or degraded	Replace RNA if necessary. Store RNA at -70°C, limit the number of freeze- thaw cycles, and keep the template on ice before the reaction.
	RNase contamination	Maintain aseptic conditions.
	RT inhibitors are present in RNA	Remove inhibitors in the RNA preparation by an additional 70% ethanol wash. Inhibitors of RT include SDS, EDTA, guanidium salts, formamide, sodium phosphate and spermidine (19, 20).
	Inefficient cDNA synthesis	Adjust cDNA synthesis temperature and/or primer design.
	Inefficient PCR amplification	Optimize PCR conditions: Adjust annealing temperature as necessary. Increase magnesium concentration. Redesign primers.
Product detected at lower-than-expected cycle number	Too much sample added to reactions	Decrease the concentration of template RNA.
Product detected at lower-than-expected cycle number, and/or positive signal from no- template controls	Template or PCR carry-over contamination	Isolate source of contamination and replace reagent(s). Use separate dedicated pipettors for reaction assembly and post-PCR analysis. Assemble reactions (except for target addition) in a DNA-free area. Use aerosol-resistant pipette tips or positive displacement pipettors.
Unexpected bands after electrophoresis	RNA contaminated with DNA	Pre-treat RNA with DNase I.
	Oligo(dT) or random primers used	Use gene-specific primers.
	Low specificity in PCR	Optimize PCR conditions as described above.
	Suboptimal primer design	Redesign primers.

Limited Use Label License No. 1: Thermostable Polymerases

Limited Use Label License No. 1: Intermostable Polymerases Use of this product is covered by one or more of the following US patents and corresponding patent claims outside the US: 5,789,224, 5,618,711, and 6,127,155. The purchase of this product includes a limited, non-transferable immunity from suit under the foregoing patent claims for using only this amount of product for the purchaser's own internal research. No right under any other patent claim, no right to perform any patented method, and no right to perform commercial services of any kind, including without limitation reporting the results of purchaser's activities for a fee or other commercial consideration, is conveyed expressly, by implication, or by estoppel. This product is for research use only. Diagnostic uses under Roche patents require a separate license from Roche. Further information on purchasing licenses may be obtained by contacting the Director of Licensing, Applied Biosystems, 850 Lincoln Centre Drive, Foster City, California 94404, USA.

Limited Use Label License No. 5: Invitrogen Technology The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product to its components or ma-terials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. For products that are subject to multiple limited use label licenses, the terms of the most restrictive limited use label license shall control. Life Technologies Corparation will not assert a claim against the buyer of infringement of patents owned or controlled by Life Technologies Corporation which cover this product based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept return of the product with a full refund. For information about purchasing a license to use this product or the technologies willing to accept return of the product with a full refund. For information about purchasing a license to use this product or the technology embedded in it for any use other than for research use please contact Out Licensing, Life Technologies, 5791 Van Allen Way, Carlsbad, California 92008; Phone (760) 603-7200 or e-mail: outlicensing@lifetch.com.

Limited Use Label License No. 14: Platinum[®] products

Technologies Corporation, under U.S. Patent Nos. 5,338,671; 5,587,287; and foreign equivalents for use in research only.

Limited Use Label License No. 223: Labeling and Detection Technology The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity) in a manner consistent with the accompanying product literature. The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to radius of the product and components or (c) materials made using this product or its components to a third party or otherwise use this product or its components for any Commercial Purposes, and that such collaborator, provided that such transfer in of for any Commercial Purposes and that such collaborator agrees in writing (a) to not transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components, whether or not such product or its components that are owned or controlled by Life Technologies Corporation will not assert a claim against the buyer of infringement of patents that are owned or controlled by Life Technologies Corporation and /or Molecular Probes, Inc., which cover this product on any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Life Technologies is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Molecular Probes, Inc., Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel; (541) 365-835

©2005, 2010 Invitrogen Corporation. All rights reserved. For research use only. Not intended for any animal or human therapeutic or diagnostic use.